1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,920 | 5,000 | 20:56 | |
| 4,920 | 5,000 | 20:56 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12.11. | Cytek Biosciences, Inc.: TIME Recognizes Cytek Biosciences as One of America's Growth Leaders of 2026 | 4 | GlobeNewswire (USA) | ||
| 06.11. | Cytek Biosciences, Inc.: Cytek Muse Micro Cell Analyzer Wins BioTech Breakthrough Award for Drug Discovery Solution of the Year | 4 | GlobeNewswire (USA) | ||
| 06.11. | Cytek reaffirms $196M-$205M 2025 revenue outlook as recurring businesses accelerate | 2 | Seeking Alpha | ||
| CYTEK BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 05.11. | Cytek Biosciences GAAP EPS of -$0.04 beats by $0.01, revenue of $52.3M beats by $1.16M | 5 | Seeking Alpha | ||
| 05.11. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 29.10. | Cytek Biosciences, Inc.: Cytek Biosciences Deepens Commitment to Expanding Access to Flow Cytometry | 1.118 | GlobeNewswire (Europe) | FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc.... ► Artikel lesen | |
| 22.10. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Third Quarter 2025 Financial Results on November 5, 2025 | 2 | GlobeNewswire (USA) | ||
| 16.10. | Cytek Biosciences Expands with New Facility in Amsterdam | 3 | Contract Pharma | ||
| 15.10. | Cytek Biosciences, Inc.: Cytek Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth | 1 | GlobeNewswire (USA) | ||
| 14.08. | Cytek Biosciences auf dem UBS Summit: Einblicke in innovative Proteomik-Technologien | 6 | Investing.com Deutsch | ||
| 07.08. | Cytek narrows 2025 revenue outlook to $196M-$205M amid recurring revenue growth and new product launches | 1 | Seeking Alpha | ||
| 06.08. | Cytek Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.08. | Cytek Biosciences, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.07. | Cytek Biosciences, Inc. (CTKB): A Bull Case Theory | 2 | Insider Monkey | ||
| 23.07. | Cytek Biosciences, Inc.: Cytek Biosciences to Report Second Quarter 2025 Financial Results on August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 24.06. | Cytek Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.06. | Cytek Biosciences (CTKB) Faced Challenges from NIH Funding Reductions | 1 | Insider Monkey | ||
| 29.05. | Cytek Biosciences, Inc.: Cytek Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora Evo Flow Cytometer | 3 | GlobeNewswire (USA) | ||
| 18.03. | Cytek Biosciences, Inc.: Cytek Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek Muse Micro System | 413 | GlobeNewswire (Europe) | FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyzer... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,026 | -4,48 % | MEDIGENE AG stürzt ab - ich traue meinen Augen kaum! | ||
| BIOFRONTERA | 2,740 | 0,00 % | PTA-News: Biofrontera AG: Die Biofrontera AG unterzeichnet einen Vertrag mit Propharma d.o.o. über den Vertrieb von Ameluz in Kroatien | DJ PTA-News: Biofrontera AG: Die Biofrontera AG unterzeichnet einen Vertrag mit Propharma d.o.o. über den Vertrieb von Ameluz® in Kroatien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera... ► Artikel lesen | |
| CLINUVEL | 6,155 | +0,16 % | Original-Research: CLINUVEL Pharmaceuticals Limited (von Parmantier & Cie. GmbH): Buy | Original-Research: CLINUVEL Pharmaceuticals Limited - from Parmantier & Cie. GmbH
30.09.2025 / 10:52 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| EDITAS MEDICINE | 2,100 | -3,05 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,060 | +5,52 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom's Macroglobulinemia in 2026 Following Advice and Guidance from Scientific... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,808 | +0,78 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update | - Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer - - Expects to... ► Artikel lesen | |
| CLEAN HARBORS | 185,00 | -0,94 % | Goldman Sachs initiates Clean Harbors stock with Neutral rating | ||
| SPERO THERAPEUTICS | 1,958 | -5,18 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update | PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero... ► Artikel lesen | |
| MESOBLAST | 1,300 | 0,00 % | Mesoblast Limited: Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids | NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that given the high... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,630 | +3,28 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - EUROPEAN COMMISSION APPROVED SUGMALIMAB FOR STAGE III NON-SMALL CELL LUNG CANCER | ||
| PROTALIX BIOTHERAPEUTICS | 1,500 | -1,96 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EST
CARMIEL, Israel, Nov. 13, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,460 | +0,22 % | XFRA NEW INSTRUMENTS AVAILABLE ON 11.11.2025 | The following instruments on XETRA do have their first trading 11.11.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.11.2025
Aktien
1 AU0000165375 Clarity Pharmaceuticals... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 86,00 | +6,83 % | Stifel hebt Kursziel für Palvella Therapeutics auf 145 Dollar an | ||
| PURPLE BIOTECH | 0,796 | -4,73 % | Purple Biotech Ltd.: Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update | Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform... ► Artikel lesen |
Das Unternehmen CYTEK BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,000 Euro und damit -1,96 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYTEK BIOSCIENCES INC finden Sie auf Wallstreet Online.